Annovis Bio, Inc. (New York Stock Exchange:ANVS)
| Market Cap | 36.06M-57.8% |
| Revenue (ttm) | 0 |
| Net Income | -49.52M-63.7% |
| EPS | -1.79+14.4% |
| Shares Out | 42.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,905,739 |
| Open | 0.70 |
| Previous Close | 0.67 |
| Day's Range | 0.63 - 0.85 |
| 52-Week Range | 0.62 - 5.50 |
| Beta | 1.35 |
| Analysts | Buy |
| Price Target | 25.67(+2938.23%) |
| Earnings Date | Nov 11, 2026 |
1 qualifying trade · 1 insider · $5.00M bought in the last 90 days
Annovis Bio, Inc. Stock Analysis — InsiderScore
See top-rated InsiderScore stocks ›Annovis Bio, Inc. scored higher than 25% of companies evaluated by InsiderBuying, and ranked 56th out of 99 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Annovis Bio, Inc. bought $5.00 million of stock across 1 purchase in the last 90 days, the largest of them $5.00 million.
The average purchase added about 100% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
About ANVS
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating ANVS in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Nov 11, 2026Earnings report
Ask Barron about ANVS
$ANVS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ANVS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ANVS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ANVS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ANVS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ANVS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ANVS
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $1.55M |
| VXFVanguard Extended Market ETF | $433.04K |
| IWCiShares Micro-Cap ETF | $62.75K |
| BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | $30.00K |
Estimated from each fund’s disclosed top holdings × AUM
ANVS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ANVS’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
Biotech: ranks #56 of 99 scored Biotech stocks · sector average 59.3
What’s Behind the Score
News check: Multiple dilutive capital raises and continued listing notice signal financial stress; no clinical/product wins mentioned.